search
Back to results

Pumps for Kids, Infants, and Neonates (PumpKIN)

Primary Purpose

Pediatric Heart Failure

Status
Active
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Surgical placement of the Jarvik 2015 VAD
Surgical Placement of Jarvik 2015 VAD
Sponsored by
Carelon Research
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Pediatric Heart Failure focused on measuring ventricular assist device, congenital heart disease, heart failure

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Children must meet all of the following criteria:

  1. Males and females within weight range 8 to 30 kg
  2. Body surface area (BSA) 0.4 m2 to 1.0 m2
  3. Cardiac Diagnosis:

    a. Standard Cardiac Anatomy : Two-ventricle circulation, including cardiomyopathy, repaired structural heart disease (e.g. anomalous left coronary artery from the pulmonary artery [ALCAPA], aortic stenosis) or acquired heart disease (e.g., myocarditis, Kawasaki disease)

  4. INTERMACS Profile 1 or 2 as evidenced by one or more of the following:

    1. Inability to wean from extra-corporeal membrane oxygenation (ECMO) or other temporary circulatory support (TCS), OR
    2. Inability to wean from mechanical ventilator support, OR
    3. Inotrope-dependent, decompensated heart failure AND meet one or more of the following criteria within 48 hours prior to implant (unless otherwise noted) which is attributed to decompensated heart failure despite optimal medical therapy:

    i. Urine output <0.5 cc/kg/hour for 12hr within 48 hours ii. Creatinine level >2 times the ULN for age iii. Alanine aminotransferase (ALT) or total bilirubin result >3 times the ULN for age (either qualifies the patient) iv. Mixed venous oxygen saturation (SvO2) <55% (or arteriovenous oxygen difference of >45%) in two repeated measurements v. Acidosis: Base excess >-5 in 2 or more measurements vi. Inability to tolerate appropriate enteral calories as prescribed by a registered dietician d. Inability to ambulate freely to participate fully in age-appropriate activities of daily living (ADLs) and/or cardiac rehabilitation/physical therapy

  5. LVAD support is intended for bridge-to transplant. Subject is listed for transplant or eligible (i.e., no medical or surgical contraindications) to be listed for cardiac transplant, United Network for Organ Sharing (UNOS) status 1A, or equivalent
  6. Written consent of parent(s) or legally authorized representative (LAR) where appropriate.

Children must not meet any of the following exclusion criteria within 48 hours prior to device implant:

  1. Known contraindication for systemic anticoagulation
  2. Currently participating in an interventional trial whose protocol prevents effective application of Jarvik 2015, potentially has an independent effect on trial endpoints, or otherwise interferes with execution of the PumpKIN protocol
  3. Stable inotrope dependence (INTERMACS profile 3)
  4. Single ventricle anatomy
  5. Presence of a mechanical heart valve
  6. Unresolved malignancy
  7. CPR with duration >30 consecutive minutes within 48 hours prior to device implant or CPR with uncertain neurological status prior to device implant
  8. Renal dysfunction that is severe or, in the opinion of the investigator, irreversible
  9. Hepatic dysfunction that is severe or, in the opinion of the investigator, irreversible
  10. Severe or irreversible pulmonary dysfunction
  11. ECMO use for >10 consecutive days
  12. Unrepairable severe aortic insufficiency
  13. Active, systemic infection unresponsive to antimicrobial therapy
  14. Known cerebrovascular event within the past 30 days or uncertain neurological status
  15. Severe right ventricular (RV) dysfunction or significant arrhythmia requiring treatment with an RV assist device (RVAD) (i.e., biventricular assist device)
  16. Unmanageable bleeding per judgment of the investigator
  17. Ventricular dysfunction that is likely to recover (e.g. myocarditis, metabolic myopathy where LV dysfunction is present solely with intermittent acidosis/crises).
  18. Left ventricular end-diastolic dimension or left ventricular end-diastolic volume z score of < +2.5 end-diastolic dimension or ventricular end-diastolic volume z score of < +3.0
  19. Left ventricular ejection fraction of >35%

Sites / Locations

  • Lucile Packard Children's Hospital Stanford
  • Children's Healthcare of Atlanta
  • Boston Children's Hospital
  • Columbia University Medical Center
  • Cincinnati Children's Hospital Medical Center
  • Children's Medical Center - Dallas
  • Texas Children's Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Jarvik 2015 Device VAD

Arm Description

New, experimental continuous flow VAD

Outcomes

Primary Outcome Measures

Clinical Feasibility
To assess the clinical feasibility of the investigational Jarvik 2015 VAD by evaluating survival in the absence of severe neurological impairment or death, or device failure up to the clinical endpoint defined as transplant, recovery or 30 days of support
Adverse Events
To evaluate the protocol defined (INTERMACS version 5.0) serious adverse events on Jarvik 2015 support up to transplant, recovery or 30 days of support
Technical, surgical, and clinical milestones assessed by feasibility milestones
To describe the technical, surgical and clinical feasibility by achieving specific technical, surgical, and clinical milestones that typically accompany a successful VAD support run
Pivotal Trial continuation assessed by exploratory primary and secondary endpoints
To evaluate patients with respect to exploratory primary and secondary endpoints to inform the choice of appropriate primary and secondary endpoints for the pivotal trial.

Secondary Outcome Measures

Incidence of Adverse Events per patient days of VAD support
The incidence rate of protocol-defined AEs (INTERMACS, version 5) per patient-day of VAD support up to the first 180 days post-implant.
Incidence of Adverse Events related to device
Incidence rate of protocol-defined AEs possibly, probably, or definitely related to the device per day of mechanical circulatory support, up to the first 180 days post-implant.
Neurological dysfunction
The incidence of new neurological dysfunction up to 180 days post-implant.
Pediatric Stroke Outcome Measure Neurological Exam (PSOM-NE) score (0 - 10 scale, higher = worse outcome)
Pediatric Stroke Outcome Measure-Neurological (PSOM-NE) score measured at 180 days post-implant or immediately prior to explant, and at 12 months post-explant.
King's Outcome Scale for Childhood Head Injury score (0 -5 scale, higher = worse outcome)
King's Outcome Scale for Childhood Head Injury (KOSCHI) score measured at 180 days post-implant or immediately prior to explant, and at 12 months post-explant.
Pediatric Stroke Recurrence and Recovery Questionnaire score (0 -10 scale, higher = worse outcome)
Pediatric Stroke Recurrence and Recovery Questionnaire (RRQ) measured at 180 days post-implant or immediately prior to explant, and at 12 months post-explant.
Vineland Adaptive Behavior Scales score (scoring and scale different by domain)
Vineland Adaptive Behavior Scales (VABS II) measured at 12 months post-explant.
Pediatric Quality of Life score (0-4 scale per domain, higher = worse outcome)
PedsQL20 measured at 180 days post-implant or immediately prior to explant and 12 months post-explant.
Ventricular Assist Device Quality of Life score (scoring and scale different per question)
VAD QL measured at 30 and 90 days post-implant, and every 90 days thereafter, while on Jarvik 2015 VAD support.
Paralytics discontinuation
Time to discontinuation of paralytics
TPN discontinuation
Time to discontinuation of total parenteral nutrition (TPN)
Extubation
Time to extubation
Inotropic agents
Time to discontinuation of inotropic agents
Sedation
Time to discontinuation of sedation such that subject is alert and interactive (e.g., engaging in age-appropriate play).
MRI
Brain Magnetic Resonance Imaging (MRI) performed 12 months post-explant to assess for clinically silent neurologic injuries.
Survival in absence of severe neurological impairment
Overall survival in the absence of a severe neurologic impairment and in the absence of device failure at 180 days following VAD implant and meeting any of the following outcomes: Survival to induction of anesthesia for cardiac transplant surgery, Recovery (removal of VAD and alive at 30 days post-explant), Survival at 180 consecutive days of VAD support
Overall survival in the absence of device failure
Overall survival in the absence of device failure but without regard for neurologic status, meeting any of the following outcomes: Survival to induction of anesthesia for cardiac transplant surgery, Survival to recovery (removal of Jarvik 2015 VAD and alive at 30 days post-explant), Survival at 180 consecutive days of Jarvik 2015 VAD support
Survival at 30 days post-implant
Survival at 30 days post-implant
Survival at 180 days post-implant
Survival at 180 days post-implant
Survival at 12 months post-explant
Survival at 12 months post-explant
Time to pump failure
Time to first pump failure
Incidence rate of pump failure
Incidence rate of pump failures
Time to first pump exchange
Time to first pump exchanges
Incidence rate of pump exchange
Incidence rate of pump exchanges
Creatinine level
Proportion of subjects with a creatinine level below the ULNULN
ALT level
Proportion of subjects with an alanine aminotransferase (ALT) level below the ULNULN

Full Information

First Posted
October 31, 2016
Last Updated
September 18, 2023
Sponsor
Carelon Research
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), Jarvik Heart, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02954497
Brief Title
Pumps for Kids, Infants, and Neonates
Acronym
PumpKIN
Official Title
Pumps for Kids, Infants, and Neonates
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 22, 2018 (Actual)
Primary Completion Date
June 9, 2023 (Actual)
Study Completion Date
September 15, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Carelon Research
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), Jarvik Heart, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
PumpKIN is a multicenter, prospective, single-arm feasibility study; Evaluating the investigational Jarvik 2015 VAD in pediatric patients with heart failure. This feasibility trial will enroll 10 subjects at up to 7 sites in the US. The primary objectives of this investigational device exemption (IDE) clinical investigation are to assess the feasibility of using the Jarvik 2015 in pediatric patients with severe heart failure who require mechanical circulatory support. Feasibility will be assessed by evaluating the safety profile of the Jarvik 2015 device in eligible subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pediatric Heart Failure
Keywords
ventricular assist device, congenital heart disease, heart failure

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Model Description
Jarvik 2015
Masking
None (Open Label)
Allocation
N/A
Enrollment
7 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Jarvik 2015 Device VAD
Arm Type
Experimental
Arm Description
New, experimental continuous flow VAD
Intervention Type
Device
Intervention Name(s)
Surgical placement of the Jarvik 2015 VAD
Intervention Description
The Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
Intervention Type
Procedure
Intervention Name(s)
Surgical Placement of Jarvik 2015 VAD
Intervention Description
Surgical Implant of the Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
Primary Outcome Measure Information:
Title
Clinical Feasibility
Description
To assess the clinical feasibility of the investigational Jarvik 2015 VAD by evaluating survival in the absence of severe neurological impairment or death, or device failure up to the clinical endpoint defined as transplant, recovery or 30 days of support
Time Frame
30 days or transplant/recovery (whichever comes first)
Title
Adverse Events
Description
To evaluate the protocol defined (INTERMACS version 5.0) serious adverse events on Jarvik 2015 support up to transplant, recovery or 30 days of support
Time Frame
30 days or transplant/recovery (whichever comes first)
Title
Technical, surgical, and clinical milestones assessed by feasibility milestones
Description
To describe the technical, surgical and clinical feasibility by achieving specific technical, surgical, and clinical milestones that typically accompany a successful VAD support run
Time Frame
up to 180 days or transplant/recovery
Title
Pivotal Trial continuation assessed by exploratory primary and secondary endpoints
Description
To evaluate patients with respect to exploratory primary and secondary endpoints to inform the choice of appropriate primary and secondary endpoints for the pivotal trial.
Time Frame
12-months post-explant
Secondary Outcome Measure Information:
Title
Incidence of Adverse Events per patient days of VAD support
Description
The incidence rate of protocol-defined AEs (INTERMACS, version 5) per patient-day of VAD support up to the first 180 days post-implant.
Time Frame
180 days post-implant
Title
Incidence of Adverse Events related to device
Description
Incidence rate of protocol-defined AEs possibly, probably, or definitely related to the device per day of mechanical circulatory support, up to the first 180 days post-implant.
Time Frame
180 days post-implant
Title
Neurological dysfunction
Description
The incidence of new neurological dysfunction up to 180 days post-implant.
Time Frame
180 days post-implant
Title
Pediatric Stroke Outcome Measure Neurological Exam (PSOM-NE) score (0 - 10 scale, higher = worse outcome)
Description
Pediatric Stroke Outcome Measure-Neurological (PSOM-NE) score measured at 180 days post-implant or immediately prior to explant, and at 12 months post-explant.
Time Frame
180 days and 12 months post-explant
Title
King's Outcome Scale for Childhood Head Injury score (0 -5 scale, higher = worse outcome)
Description
King's Outcome Scale for Childhood Head Injury (KOSCHI) score measured at 180 days post-implant or immediately prior to explant, and at 12 months post-explant.
Time Frame
180 days and 12 months post-explant
Title
Pediatric Stroke Recurrence and Recovery Questionnaire score (0 -10 scale, higher = worse outcome)
Description
Pediatric Stroke Recurrence and Recovery Questionnaire (RRQ) measured at 180 days post-implant or immediately prior to explant, and at 12 months post-explant.
Time Frame
180 days and 12 months post-explant
Title
Vineland Adaptive Behavior Scales score (scoring and scale different by domain)
Description
Vineland Adaptive Behavior Scales (VABS II) measured at 12 months post-explant.
Time Frame
12 months post-explant
Title
Pediatric Quality of Life score (0-4 scale per domain, higher = worse outcome)
Description
PedsQL20 measured at 180 days post-implant or immediately prior to explant and 12 months post-explant.
Time Frame
12 months post-explant
Title
Ventricular Assist Device Quality of Life score (scoring and scale different per question)
Description
VAD QL measured at 30 and 90 days post-implant, and every 90 days thereafter, while on Jarvik 2015 VAD support.
Time Frame
30 days, 90 days, 12 months post-explant
Title
Paralytics discontinuation
Description
Time to discontinuation of paralytics
Time Frame
12 months post-explant
Title
TPN discontinuation
Description
Time to discontinuation of total parenteral nutrition (TPN)
Time Frame
12 months post-explant
Title
Extubation
Description
Time to extubation
Time Frame
30 days post-implant
Title
Inotropic agents
Description
Time to discontinuation of inotropic agents
Time Frame
12 months post-explant
Title
Sedation
Description
Time to discontinuation of sedation such that subject is alert and interactive (e.g., engaging in age-appropriate play).
Time Frame
30 days post-implant
Title
MRI
Description
Brain Magnetic Resonance Imaging (MRI) performed 12 months post-explant to assess for clinically silent neurologic injuries.
Time Frame
12 months post-explant
Title
Survival in absence of severe neurological impairment
Description
Overall survival in the absence of a severe neurologic impairment and in the absence of device failure at 180 days following VAD implant and meeting any of the following outcomes: Survival to induction of anesthesia for cardiac transplant surgery, Recovery (removal of VAD and alive at 30 days post-explant), Survival at 180 consecutive days of VAD support
Time Frame
180 days or tranplant/recovery (whichever comes first)
Title
Overall survival in the absence of device failure
Description
Overall survival in the absence of device failure but without regard for neurologic status, meeting any of the following outcomes: Survival to induction of anesthesia for cardiac transplant surgery, Survival to recovery (removal of Jarvik 2015 VAD and alive at 30 days post-explant), Survival at 180 consecutive days of Jarvik 2015 VAD support
Time Frame
180 days or tranplant/recovery (whichever comes first)
Title
Survival at 30 days post-implant
Description
Survival at 30 days post-implant
Time Frame
30 days post-implant
Title
Survival at 180 days post-implant
Description
Survival at 180 days post-implant
Time Frame
180 days post-implant
Title
Survival at 12 months post-explant
Description
Survival at 12 months post-explant
Time Frame
12 months post-explant
Title
Time to pump failure
Description
Time to first pump failure
Time Frame
device explant
Title
Incidence rate of pump failure
Description
Incidence rate of pump failures
Time Frame
device explant
Title
Time to first pump exchange
Description
Time to first pump exchanges
Time Frame
device explant
Title
Incidence rate of pump exchange
Description
Incidence rate of pump exchanges
Time Frame
device explant
Title
Creatinine level
Description
Proportion of subjects with a creatinine level below the ULNULN
Time Frame
180 days or immediately prior to explant
Title
ALT level
Description
Proportion of subjects with an alanine aminotransferase (ALT) level below the ULNULN
Time Frame
180 days or immediately prior to explant

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Children must meet all of the following criteria: Males and females within weight range 8 to 30 kg Body surface area (BSA) 0.4 m2 to 1.0 m2 Cardiac Diagnosis: a. Standard Cardiac Anatomy : Two-ventricle circulation, including cardiomyopathy, repaired structural heart disease (e.g. anomalous left coronary artery from the pulmonary artery [ALCAPA], aortic stenosis) or acquired heart disease (e.g., myocarditis, Kawasaki disease) INTERMACS Profile 1 or 2 as evidenced by one or more of the following: Inability to wean from extra-corporeal membrane oxygenation (ECMO) or other temporary circulatory support (TCS), OR Inability to wean from mechanical ventilator support, OR Inotrope-dependent, decompensated heart failure AND meet one or more of the following criteria within 48 hours prior to implant (unless otherwise noted) which is attributed to decompensated heart failure despite optimal medical therapy: i. Urine output <0.5 cc/kg/hour for 12hr within 48 hours ii. Creatinine level >2 times the ULN for age iii. Alanine aminotransferase (ALT) or total bilirubin result >3 times the ULN for age (either qualifies the patient) iv. Mixed venous oxygen saturation (SvO2) <55% (or arteriovenous oxygen difference of >45%) in two repeated measurements v. Acidosis: Base excess >-5 in 2 or more measurements vi. Inability to tolerate appropriate enteral calories as prescribed by a registered dietician d. Inability to ambulate freely to participate fully in age-appropriate activities of daily living (ADLs) and/or cardiac rehabilitation/physical therapy LVAD support is intended for bridge-to transplant. Subject is listed for transplant or eligible (i.e., no medical or surgical contraindications) to be listed for cardiac transplant, United Network for Organ Sharing (UNOS) status 1A, or equivalent Written consent of parent(s) or legally authorized representative (LAR) where appropriate. Children must not meet any of the following exclusion criteria within 48 hours prior to device implant: Known contraindication for systemic anticoagulation Currently participating in an interventional trial whose protocol prevents effective application of Jarvik 2015, potentially has an independent effect on trial endpoints, or otherwise interferes with execution of the PumpKIN protocol Stable inotrope dependence (INTERMACS profile 3) Single ventricle anatomy Presence of a mechanical heart valve Unresolved malignancy CPR with duration >30 consecutive minutes within 48 hours prior to device implant or CPR with uncertain neurological status prior to device implant Renal dysfunction that is severe or, in the opinion of the investigator, irreversible Hepatic dysfunction that is severe or, in the opinion of the investigator, irreversible Severe or irreversible pulmonary dysfunction ECMO use for >10 consecutive days Unrepairable severe aortic insufficiency Active, systemic infection unresponsive to antimicrobial therapy Known cerebrovascular event within the past 30 days or uncertain neurological status Severe right ventricular (RV) dysfunction or significant arrhythmia requiring treatment with an RV assist device (RVAD) (i.e., biventricular assist device) Unmanageable bleeding per judgment of the investigator Ventricular dysfunction that is likely to recover (e.g. myocarditis, metabolic myopathy where LV dysfunction is present solely with intermittent acidosis/crises). Left ventricular end-diastolic dimension or left ventricular end-diastolic volume z score of < +2.5 end-diastolic dimension or ventricular end-diastolic volume z score of < +3.0 Left ventricular ejection fraction of >35%
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William T Mahle, MD
Organizational Affiliation
Children's Hospital of Atlanta, Emory University School of Medicine
Official's Role
Study Chair
Facility Information:
Facility Name
Lucile Packard Children's Hospital Stanford
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Facility Name
Children's Healthcare of Atlanta
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Boston Children's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Columbia University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
Cincinnati Children's Hospital Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229
Country
United States
Facility Name
Children's Medical Center - Dallas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75235
Country
United States
Facility Name
Texas Children's Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Limited use data set will be made available through NHLBI after the conclusion of the trial.

Learn more about this trial

Pumps for Kids, Infants, and Neonates

We'll reach out to this number within 24 hrs